Dianthus Therapeutics (DNTH) vs MBX Biosciences (MBX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
MBX Biosciences (MBX) has outperformed Dianthus Therapeutics (DNTH) over the past year, gaining 245.2% versus a gain of 144.6%. Dianthus Therapeutics is the larger company by market cap ($4.75 billion vs $2.63 billion), about 1.8 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNTH | MBX |
|---|---|---|
| Share price | $84.88 | $54.54 |
| Market cap | $4.75B | $2.63B |
| 1-day change | -0.61% | -4.18% |
| YTD return | +105.97% | +72.92% |
| 1-year return | +144.61% | +245.19% |
| 5-year return | -21.17% | — |
| EPS (TTM) | $-4.21 | $-2.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.04M | — |
| Revenue growth (YoY) | -67.35% | — |
| Net income (latest FY) | $-162.34M | $-87.00M |
| Operating margin | -8739.34% | — |
| Net margin | -7973.33% | — |
| 52-week high | $117.88 | $72.64 |
| 52-week low | $32.22 | $12.94 |
| Distance from 52-week high | -27.99% | -24.92% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +65.88% | +72.90% |
| Average volume | 825.33K | 556.72K |
| Shares outstanding | 55.93M | 48.16M |
| Employees | 92 | 63 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MBX has outperformed DNTH by 100.6 percentage points over the past year.
About Dianthus Therapeutics
DNTH stock →Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function.
Healthcare · Biotechnology · 92 employees
About MBX Biosciences
MBX stock →MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism.
Healthcare · Biotechnology · 63 employees
DNTH vs MBX FAQ
Which is bigger, Dianthus Therapeutics or MBX Biosciences?
Dianthus Therapeutics (DNTH) is larger, with a market capitalization of $4.75B compared with $2.63B for MBX Biosciences (MBX).
Which stock has performed better over the past year, DNTH or MBX?
MBX returned +245.19% over the past 12 months, compared with +144.61% for DNTH (price return, excluding dividends). Past performance does not predict future results.
Are Dianthus Therapeutics and MBX Biosciences in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.